Underuse of statins in patients with atherosclerotic ischemic stroke in China

Chinese Medical Journal

Volumn 125, Issue 10, 2012, Pages 1703-1707

  Li, Xi ^a   Gao, Yan ^b   Li, Jing ^b   Feng, Fang ^b   Liu, Jia Min ^b   Zhang, Hai Bo ^b   Zhang, Dan ^b   Hundei, Wu Han Bi Li Ge ^b   Chen, Fang ^c   Chen, Yi Ping ^c   Chen, Zheng Ming ^c   Landray, Martin ^c   Armitage, Jane ^c   Jiang, Li Xin ^b   Li, Li Ming ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b FUWAI HOSPITAL   (China)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Ischemic stroke; Secondary prevention

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CHINA; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; UNIVERSITY HOSPITAL; CEREBROVASCULAR ACCIDENT; MIDDLE AGED;

AGED; CHINA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; STROKE;

EID: 84871683323     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.10.005     Document Type: Article

References (21)

1. World Health Organization. Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002.
2. WHO Regional Office for the Western Pacific. Noncommunicable Disease and Poverty: The Need for Pro-poor Strategies in the Western Pacific Region - A Review: World Health Organization; 2007.
3. Chinese Medical Association Ischemic Stroke Guidelines Working Group. Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. Chin J Neurol (Chin) 2010; 43: 154-160.
4. World Health Organization. Disease and injury country estimates: burden of disease. 2008. (Accessed February 8, 2012 at http://www.who.int/healthinfo/global_burden_ disease/estimates_country/en/index.html.)
5. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
6. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20 536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767.
9. Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
10. Vergouwen MDI, de Haan RJ, Vermeulen M, Roos YBWEM. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008; 39: 497-502.
11. Kent DM. Stroke-an equal opportunity for the initiation of statin therapy. N Engl J Med 2006; 355: 613-615.
12. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 227-276.
13. Expert Group on Prevention of Statins on Ischemic Stroke/TIA. Expert consensus on prevention of statins on ischemic stroke/TIA. Chin J Intern Med (Chin) 2007; 46: 81-83.
14. Ma RH, Wang YJ, Wang CX, Zhao XQ, Wang YL, Xu MJ, et al. A survey on cerebral infarction/transient ischemic attack inpatients compliance with secondary stroke prevention and follow-up 90 days. Chin Med J 2008; 88: 2618-2622.
15. Wang LX, Dong Y, Fang K, Dong Q. A study on medication in the secondary prevention of ischemic stroke. Chin J Cerebrovasc Dis (Electronic Version) (Chin) 2010; 4: 9-14.
16. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99: 410-414.
17. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 2007; 6: 456-464.
18. Guan F, Xie J, Wang GL, Wang JH, Wang JS, Yu JM, et al. Community-wide survey of physicians' knowledge of cholesterol management. Chin Med J 2010; 123: 884-889.
19. Kesteloot H, Huang DX, Yang XS, Claes J, Rosseneu M, Geboers J, et al. Serum lipids in the People's Republic of China. Comparison of Western and Eastern populations. Arteriosclerosis 1985; 5: 427-433.
20. National bureau of statistics of China. China statistical yearbook 2010. National bureau of statistics of China, 2010. (Accessed February 8th, 2012 at http://www.stats.gov.cn/ tjsj/ndsj/2008/html/J0902e.htm.)
21. Jiang LX, Li X, Li J, Feng F, Chen YP, Chen ZM, et al. A cross-sectional study on statin use among patients with atherosclerotic ischemic stroke in China. Chin J Epidemiol (Chin) 2010; 31: 85-88.